Literature DB >> 29915283

Upregulation of microRNA-3129 suppresses epithelial ovarian cancer through CD44.

Xiaochun Sun1,2, Manhua Cui3, Lingling Tong2, Aichen Zhang2, Kun Wang2.   

Abstract

The purpose of this work is to evaluate whether human microRNA-3129 (hsa-miR-3129) may functionally regulate cancer development, possibly through downstream target CD44 in human epithelial ovarian cancer (EOC). Direct targeting of hsa-miR-3129 on human CD44 transcript was evaluated using a dual-luciferase reporter assay. Gene expression of hsa-miR-3129 in immortal EOC cell lines was evaluated by qRT-PCR. Lentivirus-mediated hsa-miR-3129 upregulation or downregulation was conducted in SK-OV-3 and CAOV-3 cells, in which endogenous hsa-miR-3129 and CD44 expressions were then measured. In hsa-miR-3129 upregulated or downregulated EOC cells, functional assays were applied to evaluate EOC proliferation, bufalin chemoresistance in vitro, or xenotransplantation in vivo. Moreover, CD44 was ectopically overexposed in hsa-miR-3129 upregulated EOC cells to functionally evaluate the correlation between hsa-miR-3129 and CD44 in EOC. Dual-luciferase reporter assay confirmed hsa-miR-3129 directly binds CD44. QRT-PCR revealed that hsa-miR-3129 was substantially downregulated in EOC cell lines. In SK-OV-3 and CAOV-3 cells, lentivirus-induced hsa-miR-3129 upregulation downregulated CD44 whereas hsa-miR-3129 downregulation did not affect CD44 expression. Hsa-miR-3129 upregulation had significant anti-cancer effects by inhibiting EOC proliferation, increasing bufalin chemoresistance, and suppressing xenotransplantation. On the other hand, overexpressing CD44 reversed the anti-cancer functions by hsa-miR-3129 upregulation in EOC cells. In conclusion, Has-miR-3129 is a functional regulator, possibly through reverse targeting on CD44, in EOC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29915283     DOI: 10.1038/s41417-018-0026-1

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  7 in total

1.  Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p.

Authors:  Lingling Tong; Yu Ao; Hejia Zhang; Kun Wang; Yunyun Wang; Qingjie Ma
Journal:  Cancer Med       Date:  2019-06-28       Impact factor: 4.452

2.  HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.

Authors:  Carolyn M Klinge; Kellianne M Piell; Christine Schaner Tooley; Eric C Rouchka
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

Review 3.  CD44 as a tumor biomarker and therapeutic target.

Authors:  Hanxiao Xu; Mengke Niu; Xun Yuan; Kongming Wu; Aiguo Liu
Journal:  Exp Hematol Oncol       Date:  2020-12-10

4.  Integrative Transcriptome-Wide Analyses Uncover Novel Risk-Associated MicroRNAs in Hormone-Dependent Cancers.

Authors:  Dulari K Jayarathna; Miguel E Rentería; Adil Malik; Emilie Sauret; Jyotsna Batra; Neha S Gandhi
Journal:  Front Genet       Date:  2021-08-26       Impact factor: 4.599

5.  PLK4 is a key molecule in the formation of PGCCs and promotes invasion and migration of progeny cells derived from PGCCs.

Authors:  Fangmei Fu; Lankai Chen; Xiaohui Yang; Linlin Fan; Mingqing Zhang; Shuo Chen; Minying Zheng; Ming Gao; Shiwu Zhang
Journal:  J Cancer       Date:  2022-07-18       Impact factor: 4.478

6.  MicroRNA-936 targets FGF2 to inhibit epithelial ovarian cancer aggressiveness by deactivating the PI3K/Akt pathway.

Authors:  Cuihong Li; Shunrui Yu; Shanshan Wu; Ying Ni; Zixuan Pan
Journal:  Onco Targets Ther       Date:  2019-07-08       Impact factor: 4.147

Review 7.  Emerging Therapeutic Agents for Colorectal Cancer.

Authors:  Marianna Nalli; Michela Puxeddu; Giuseppe La Regina; Stefano Gianni; Romano Silvestri
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.